Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine

L19‐tumor necrosis factor alpha (L19mTNF‐α; L), a fusion protein consisting of mouse TNFα and the human antibody fragment L19 directed to the extra domain‐B (ED‐B) of fibronectin, is able to selectively target tumor vasculature and to exert a long‐lasting therapeutic activity in combination with melphalan (M) in syngeneic mouse tumor models. We have studied the antitumor activity of single L19mTNF‐α treatment in combination with melphalan and gemcitabine (G) using different administration protocols in two histologically different murine tumor models: WEHI‐164 fibrosarcoma and K7M2 osteosarcoma. All responding mice showed significant reduction in myeloid‐derived suppressor cells (MDSCs) and an increase in CD4+ and CD8+ T cells in the tumor infiltrates, as well as significant reduction in regulatory T cells (Treg) at the level of draining lymph nodes. What is important is that all cured mice rejected tumor challenge up to 1 year after therapy. Targeted delivery of L19mTNF‐α synergistically increases the antitumor activity of melphalan and gemcitabine, but optimal administration schedules are required. This study provides information for designing clinical studies using L19mTNF‐α in combination with chemotherapeutic drugs.

• Publication year

  2013

• Venue

  Cancer Medicine

• Publication date

  2013-05-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cam4.89PMID 24156020PMCID 3799282
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Coordinated regulation of myeloid cells by tumours

  2012cited by this paper
• Targeting TNF-α to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy

  2012cited by this paper
• Regulatory T cells and immune tolerance to tumors

  2010cited by this paper
• Therapy‐induced antitumor vaccination in neuroblastomas by the combined targeting of IL‐2 and TNFα

  2010cited by this paper
• Cross-Talk between Myeloid-Derived Suppressor Cells and Macrophages Subverts Tumor Immunity toward a Type 2 Response1

  2007cited by this paper
• Therapy‐induced antitumor vaccination by targeting tumor necrosis factor‐α to tumor vessels in combination with melphalan

  2007cited by this paper
• A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.

  2007cited by this paper
• CIITA-Induced MHC Class II Expression in Mammary Adenocarcinoma Leads to a Th1 Polarization of the Tumor Microenvironment, Tumor Rejection, and Specific Antitumor Memory

  2006cited by this paper
• Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin.

  2006cited by this paper
• Synergistic Antitumor Activity of Cisplatin, Paclitaxel, and Gemcitabine with Tumor Vasculature-Targeted Tumor Necrosis Factor-α

  2006cited by this paper
• Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy.

  2005cited by this paper
• Tumor antigen-specific T helper cells in cancer immunity and immunotherapy

  2005cited by this paper
• Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity

  2005cited by this paper
• Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.

  2004cited by this paper
• CD4+ Tregs and immune control.

  2004cited by this paper
• Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer.

  2003cited by this paper
• Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells1

  2003cited by this paper
• Selective targeted delivery of TNFalpha to tumor blood vessels.

  2003cited by this paper
• Advanced pancreatic cancer: is there a role for combination therapy?

  2003cited by this paper
• Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens

  2002cited by this paper
• Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy.

  2002cited by this paper
• Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.

  2002cited by this paper
• Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin.

  2002cited by this paper
• Systemic therapy for advanced pancreatic cancer

  2002cited by this paper
• Gemcitabine-containing regimens in bladder cancer: A new standard of care.

  2001cited by this paper
• Tumor-induced immune dysfunctions caused by myeloid suppressor cells.

  2001cited by this paper
• Gemcitabine in ovarian cancer.

  2001cited by this paper
• Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance

  2001cited by this paper
• Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

  2000cited by this paper
• The role of gemcitabine alone and in combination in the treatment of pancreatic cancer

  2000cited by this paper
• Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.

  1999cited by this paper
• HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY A High-Affinity Human Antibody That Targets Tumoral Blood Vessels

  1999cited by this paper
• Preclinical, pharmacologic, and phase I studies of gemcitabine.

  1997cited by this paper
• Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts.

  1996cited by this paper
• Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1

  1995cited by this paper
• The fibronectin isoform containing the ed‐b oncofetal domain: A marker of angiogenesis

  1994cited by this paper
• Tumor‐necrosis factor can enhance radio‐antibody uptake in human colon carcinoma xenografts by increasing vascular permeability

  1993cited by this paper
• Relationship between tissue factor expression and deposition of fibrin, platelets, and leukocytes on cultured endothelial cells under venous blood flow conditions.

  1993cited by this paper
• Toxic effect of tumor necrosis factor on tumor vasculature in mice.

  1988cited by this paper
• This is an author version of the contribution published on: Questa è la versione dell’autore dell’opera: Selective targeted delivery of TNFα to tumor blood vessels

  year unknowncited by this paper

• Osteosarcoma immune microenvironment: cellular struggle and novel therapeutic insights

  2025cites this paper
• Immunotherapy of osteosarcoma based on immune microenvironment modulation

  2025cites this paper
• Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications

  2022cites this paper
• The anti-osteosarcoma effect from panax notoginseng saponins by inhibiting the G0 / G1 phase in the cell cycle and affecting p53-mediated autophagy and mitochondrial apoptosis

  2021cites this paper
• Research models and mesenchymal/epithelial plasticity of osteosarcoma

  2021cites this paper
• Clinicopathological and prognostic values of fibronectin and integrin αvβ3 expression in primary osteosarcoma

  2019cites this paper
• Tumor Vasculature Targeted TNFα Therapy: Reversion of Microenvironment Anergy and Enhancement of the Anti-tumor Efficiency.

  2018cites this paper
• Proton pump inhibitor use and cancer mortality

  2018cites this paper
• Strategy to targeting the immune resistance and novel therapy in colorectal cancer

  2018cites this paper
• Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma

  2018cites this paper
• Evaluation of F8-TNF-α in Models of Early and Progressive Metastatic Osteosarcoma

  2017influential citation
• The therapeutic T‐cell response induced by tumor delivery of TNF and melphalan is dependent on early triggering of natural killer and dendritic cells

  2017cites this paper
• Combinatorial prospects of nano-targeted chemoimmunotherapy.

  2016cites this paper
• Positive and Negative Impact of Immune Cells on Disease Outcome in Cancer Patients Treated with Chemotherapy Cells Markers Cancer Type

  2015cites this paper
• Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.

  2015cites this paper
• Large Molecule Therapeutics A Chemically De fi ned Trifunctional Antibody – Cytokine – Drug Conjugate with Potent Antitumor Activity

  2014cites this paper
• A Chemically Defined Trifunctional Antibody–Cytokine–Drug Conjugate with Potent Antitumor Activity

  2014cites this paper
• A chemically-defined trifunctional antibody-cytokine-drug conjugate with potent anti- tumor activity Running Title: An antibody-cytokine-drug conjugate with anti-tumor activity

  2014cites this paper